Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2013, Vol. 18 ›› Issue (8): 868-873.

Previous Articles     Next Articles

Fenofibrate inhibits cardiac hypertrophy by up-regulation of short-chain acyl-CoA dehydrogenase

ZHOU Si-gui1, XU Li-peng2, LU Yao3, YUAN Xi3, PAN Xue-diao1, ZANG Lin-quan1   

  1. 1Department of Clinical Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, Guangdong, China;
    2Institute of New Drug Research, Jinan University College of Pharmacy, Guangzhou 510632, Guangdong, China;
    3Clinical Medicine Eight Years 1st Class 2007 Grade, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, Guangdong, China
  • Received:2013-02-04 Revised:2013-06-26 Online:2013-08-26 Published:2013-07-31

Abstract: AIM: To investigate the effect of fenofibrate on the expression of short-chain acyl-CoA dehydrogenase (SCAD), cardiac lipid metabolism and cardiac hypertrophy in spontaneously hypertensive rats (SHR).METHODS: SHR were given fenofibrate for 8 weeks, then systolic pressure and the ratios of left ventricular weight to body weight, free fatty acid in blood serum and cardiac muscle were measured. The expression of PPARα and SCAD in myocardium were investigated by western blot. Enzyme activity of SCAD in myocardium was measured with the anaerobic electron transfer flavoprotein fluorescence reduction assay.RESULTS: Compared with WKY rats, systolic blood pressure and the ratios of left ventricular weight to body weight were markedly elevated in SHR. The expression of PPARα and SCAD in myocardium of SHR were decreased as compared with WKY group. The activity of SCAD in myocardium was lower than that in WKY rats. Free fatty acid in blood serum and cardiac muscle were higher than that in WKY rats. Compared with SHR, fenofibrate decreased the ratios of left ventricular weight to body weight, but had no effect on systolic blood pressure. After treated with fenofibrate, the expression of PPARα and SCAD in myocardium of SHR was increased in associated with lower contents of free fatty acid in blood serum and cardiac muscle.CONCLUSION: Fenofibrate may ameliorate cardiac hypertrophy by increasing the expression of SCAD and improving cardiac energy metabolism in SHR.

Key words: Fenofibrate, Cardiac hypertrophy, Peroxisome proliferators activated receptor, Short-chain acyl-CoA dehydrogenase, Fatty acid oxidation

CLC Number: